Mohali plant supply suspension continues
Supplies from Mohali have not resumed; residual inventory sales are declining. Market share loss may be permanent depending on competition and contracts.
high · analyst_question
Sunpharma Ltd — Q1 FY24
Sun Pharma reported Q1 FY24 consolidated revenue of INR 11,785 crore, up 10.7% YoY, driven by US specialty growth (up 21% to $232M) and episodic lenalidomide sales.
neutral
medium
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
India market share decline and NLEM impact
India market share fell to 8.33% from 8.5% due to NLEM price cuts and sitagliptin patent expiry. Recovery timeline uncertain.
medium · management_commentaryTaro acquisition uncertainty
Management provided no update on the Taro minority buyout beyond forming a special committee. Strategic benefits remain unclear.
medium · analyst_questionSpecialty R&D pipeline execution risk
Multiple Phase II/III trials (ILUMYA PsA, deuruxo, GLP-1) require significant investment. Failure or delay could impact returns.
medium · data_observation